Clinical experiment designed to assess clinical efficacy targeting MCI in mouse. Primary outcome: Validate Brain Connectivity-Targeted tACS Trial in Early AD
Description
Brain Connectivity-Targeted tACS Trial in Early AD
Background and Rationale
Alzheimer's disease (AD) pathogenesis involves early network dysfunction preceding overt neurodegeneration, with resting-state fMRI revealing paradoxical hyperconnectivity in default mode network (DMN) regions during mild cognitive impairment (MCI) stages. This hyperconnectivity may facilitate trans-synaptic spread of pathological tau protein through anatomically connected brain regions, accelerating disease progression. Transcranial alternating current stimulation (tACS) offers a non-invasive neuromodulation approach to normalize aberrant network activity by applying weak electrical currents at specific frequencies to targeted brain regions. This randomized, double-blind, sham-controlled trial evaluates whether personalized tACS protocols targeting hyperconnected DMN nodes can restore physiological connectivity patterns and slow cognitive decline in early AD patients. The study employs a precision medicine approach, using baseline resting-state fMRI to identify individual-specific hyperconnectivity patterns and design personalized stimulation montages....
Brain Connectivity-Targeted tACS Trial in Early AD
Background and Rationale
Alzheimer's disease (AD) pathogenesis involves early network dysfunction preceding overt neurodegeneration, with resting-state fMRI revealing paradoxical hyperconnectivity in default mode network (DMN) regions during mild cognitive impairment (MCI) stages. This hyperconnectivity may facilitate trans-synaptic spread of pathological tau protein through anatomically connected brain regions, accelerating disease progression. Transcranial alternating current stimulation (tACS) offers a non-invasive neuromodulation approach to normalize aberrant network activity by applying weak electrical currents at specific frequencies to targeted brain regions. This randomized, double-blind, sham-controlled trial evaluates whether personalized tACS protocols targeting hyperconnected DMN nodes can restore physiological connectivity patterns and slow cognitive decline in early AD patients. The study employs a precision medicine approach, using baseline resting-state fMRI to identify individual-specific hyperconnectivity patterns and design personalized stimulation montages. Participants receive 20 sessions of gamma-frequency (40 Hz) tACS targeting posterior cingulate cortex and precuneus, key DMN hubs showing consistent hyperconnectivity in early AD. Primary endpoints include changes in DMN connectivity measured via resting-state fMRI and cognitive performance on episodic memory tasks. Secondary outcomes encompass cerebrospinal fluid biomarkers (tau, phospho-tau, amyloid-beta), structural MRI volumetrics, and functional connectivity in other networks. This innovative approach represents a paradigm shift from symptom management toward mechanism-based intervention, potentially offering the first disease-modifying treatment targeting network pathophysiology in early AD.
This experiment directly tests predictions arising from the following hypotheses:
Gamma entrainment therapy to restore hippocampal-cortical synchrony
Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation
Prefrontal sensory gating circuit restoration via PV interneuron enhancement
Sleep Spindle-Synaptic Plasticity Enhancement
HCN1-Mediated Resonance Frequency Stabilization Therapy
Experimental Protocol
Phase 1 (Screening, Days -14 to 0): Screen participants meeting MCI criteria with evidence of AD pathology via CSF biomarkers or PET imaging. Conduct baseline assessments including resting-state fMRI (10-minute acquisition), structural MRI, comprehensive neuropsychological battery (ADAS-Cog, MoCA, episodic memory tests), and lumbar puncture for biomarkers. N=60 participants randomized 1:1 to active tACS versus sham. Phase 2 (Stimulation Protocol, Days 1-28): Deliver personalized tACS using individual fMRI connectivity maps to position electrodes over hyperconnected DMN regions. Apply 40 Hz stimulation at 2 mA peak-to-peak intensity for 20 minutes per session, 5 sessions weekly for 4 weeks. Sham group receives identical setup with imperceptible current (30 seconds ramp-up only). Monitor adverse events and tolerability daily. Phase 3 (Immediate Assessment, Days 29-35): Repeat baseline assessments including resting-state fMRI, cognitive testing, and biomarker sampling within one week post-intervention. Phase 4 (Follow-up, Days 90, 180): Conduct longitudinal assessments at 3 and 6 months to evaluate durability of effects. Primary endpoint: change in posterior cingulate-hippocampal connectivity strength. Secondary endpoints: episodic memory composite score, CSF p-tau181 levels, and whole-brain network topology metrics. Statistical analysis via mixed-effects models controlling for baseline connectivity, APOE genotype, and disease severity.
Expected Outcomes
Active tACS group will show 20-30% reduction in hyperconnectivity between posterior cingulate cortex and hippocampus compared to 5% change in sham group (effect size d=0.8, p<0.01)
Episodic memory composite scores will improve by 0.5-0.7 standard deviations in active group versus 0.1 decline in sham group at 1-month follow-up
CSF phospho-tau181 levels will decrease by 15-25% in active stimulation group while remaining stable or increasing by 5-10% in sham group
Network efficiency metrics will normalize toward healthy control values in active group, with 20-30% improvement in global efficiency measures
Benefits will persist at 3-month follow-up with 60-70% retention of connectivity improvements, demonstrating lasting neuroplasticity effects
Responder analysis will identify 70-80% of active tACS participants showing clinically meaningful connectivity normalization versus 20-30% in sham group
Success Criteria
• Statistically significant reduction in DMN hyperconnectivity (p<0.05) with effect size >0.6 compared to sham group
• Improvement in episodic memory composite score ≥0.5 SD above sham group with 95% confidence interval excluding zero
• ≥15% reduction in CSF phospho-tau181 levels in active group versus stable/increased levels in sham group
• Treatment-related serious adverse events <5% with no significant difference in mild side effects between groups
• ≥60% of active tACS participants classified as 'responders' based on >20% connectivity normalization
• Durability of effects with ≥50% retention of primary outcome benefits at 3-month follow-up assessment
TARGET GENE
MCI
MODEL SYSTEM
mouse
ESTIMATED COST
$730,000
TIMELINE
22 months
PATHWAY
N/A
SOURCE
wiki
PRIMARY OUTCOME
Validate Brain Connectivity-Targeted tACS Trial in Early AD
Phase 1 (Screening, Days -14 to 0): Screen participants meeting MCI criteria with evidence of AD pathology via CSF biomarkers or PET imaging. Conduct baseline assessments including resting-state fMRI (10-minute acquisition), structural MRI, comprehensive neuropsychological battery (ADAS-Cog, MoCA, episodic memory tests), and lumbar puncture for biomarkers. N=60 participants randomized 1:1 to active tACS versus sham. Phase 2 (Stimulation Protocol, Days 1-28): Deliver personalized tACS using individual fMRI connectivity maps to position electrodes over hyperconnected DMN regions. Apply 40 Hz stimulation at 2 mA peak-to-peak intensity for 20 minutes per session, 5 sessions weekly for 4 weeks. Sham group receives identical setup with imperceptible current (30 seconds ramp-up only).
...
Phase 1 (Screening, Days -14 to 0): Screen participants meeting MCI criteria with evidence of AD pathology via CSF biomarkers or PET imaging. Conduct baseline assessments including resting-state fMRI (10-minute acquisition), structural MRI, comprehensive neuropsychological battery (ADAS-Cog, MoCA, episodic memory tests), and lumbar puncture for biomarkers. N=60 participants randomized 1:1 to active tACS versus sham. Phase 2 (Stimulation Protocol, Days 1-28): Deliver personalized tACS using individual fMRI connectivity maps to position electrodes over hyperconnected DMN regions. Apply 40 Hz stimulation at 2 mA peak-to-peak intensity for 20 minutes per session, 5 sessions weekly for 4 weeks. Sham group receives identical setup with imperceptible current (30 seconds ramp-up only). Monitor adverse events and tolerability daily. Phase 3 (Immediate Assessment, Days 29-35): Repeat baseline assessments including resting-state fMRI, cognitive testing, and biomarker sampling within one week post-intervention. Phase 4 (Follow-up, Days 90, 180): Conduct longitudinal assessments at 3 and 6 months to evaluate durability of effects. Primary endpoint: change in posterior cingulate-hippocampal connectivity strength. Secondary endpoints: episodic memory composite score, CSF p-tau181 levels, and whole-brain network topology metrics. Statistical analysis via mixed-effects models controlling for baseline connectivity, APOE genotype, and disease severity.
Expected Outcomes
Active tACS group will show 20-30% reduction in hyperconnectivity between posterior cingulate cortex and hippocampus compared to 5% change in sham group (effect size d=0.8, p<0.01)
Episodic memory composite scores will improve by 0.5-0.7 standard deviations in active group versus 0.1 decline in sham group at 1-month follow-up
CSF phospho-tau181 levels will decrease by 15-25% in active stimulation group while remaining stable or increasing by 5-10% in sham group
Network efficiency metrics will normalize toward healthy control values in active group, with 20-30% improvement in global effi
...
Active tACS group will show 20-30% reduction in hyperconnectivity between posterior cingulate cortex and hippocampus compared to 5% change in sham group (effect size d=0.8, p<0.01)
Episodic memory composite scores will improve by 0.5-0.7 standard deviations in active group versus 0.1 decline in sham group at 1-month follow-up
CSF phospho-tau181 levels will decrease by 15-25% in active stimulation group while remaining stable or increasing by 5-10% in sham group
Network efficiency metrics will normalize toward healthy control values in active group, with 20-30% improvement in global efficiency measures
Benefits will persist at 3-month follow-up with 60-70% retention of connectivity improvements, demonstrating lasting neuroplasticity effects
Responder analysis will identify 70-80% of active tACS participants showing clinically meaningful connectivity normalization versus 20-30% in sham group
Success Criteria
• Statistically significant reduction in DMN hyperconnectivity (p<0.05) with effect size >0.6 compared to sham group
• Improvement in episodic memory composite score ≥0.5 SD above sham group with 95% confidence interval excluding zero
• ≥15% reduction in CSF phospho-tau181 levels in active group versus stable/increased levels in sham group
• Treatment-related serious adverse events <5% with no significant difference in mild side effects between groups
• ≥60% of active tACS participants classified as 'responders' based on >20% connectivity normalization
• Durability of effects with ≥
...
• Statistically significant reduction in DMN hyperconnectivity (p<0.05) with effect size >0.6 compared to sham group
• Improvement in episodic memory composite score ≥0.5 SD above sham group with 95% confidence interval excluding zero
• ≥15% reduction in CSF phospho-tau181 levels in active group versus stable/increased levels in sham group
• Treatment-related serious adverse events <5% with no significant difference in mild side effects between groups
• ≥60% of active tACS participants classified as 'responders' based on >20% connectivity normalization
• Durability of effects with ≥50% retention of primary outcome benefits at 3-month follow-up assessment